
FDMT Stock Forecast & Price Target
FDMT Analyst Ratings
Bulls say
4D Molecular Therapeutics is making significant progress in their Phase III clinical trials for 4D-150, which has a $8.82 NPV/share valuation and high potential to penetrate the wet AMD and DME markets with initial pricing at $70,000 per eye. The biggest risk to their success lies in their manufacturing capabilities, as AAV-based GT products are novel and could face delays or constraints if sufficient capacity is not developed.
Bears say
4D Molecular Therapeutics is currently ramping sales, but may face challenges in achieving profitability due to the need for additional financing and potential competition from other therapies. While their technology for targeted gene therapy delivery is promising, the clinical data for their lead therapy 4D-710 in cystic fibrosis show variable efficacy and further studies are needed to confirm its clinical benefit. Additionally, regulatory and manufacturing hurdles may also impact the success of their pipeline products.
This aggregate rating is based on analysts' research of 4D Molecular Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
FDMT Analyst Forecast & Price Prediction
Start investing in FDMT
Order type
Buy in
Order amount
Est. shares
0 shares